We are
rewriting
the biology
of aging.
Shift Biosciences develops next-generation epigenetic and cellular therapies to extend healthy human lifespan.
“Aging is not an inevitability. It is a biological program. And programs can be rewritten.”
For too long, aging has been treated as a fixed constraint on human life — something to be managed, not solved. At Shift, we reject that premise entirely. The molecular mechanisms of aging are becoming legible, and with that legibility comes the possibility of intervention.
We are building a new generation of therapeutics that engage directly with the biological programs responsible for cellular decline, epigenetic drift, and tissue dysfunction. Our mission is not to slow the clock — it is to reset it.
Three therapeutic axes.
Epigenetic Reprogramming
Epigenetic clocks — patterns of DNA methylation — encode biological age at the cellular level. Our partial reprogramming platform uses transient expression of Yamanaka factors to reset these clocks without triggering pluripotency, restoring youthful gene expression in aged tissues. SR-001 is our lead asset in this axis, targeting aging-associated fibrosis in multiple organ systems.
Senolytic Clearance
Senescent cells accumulate with age and drive chronic inflammation through their secretory phenotype (SASP), accelerating tissue deterioration across organ systems. Our next-generation senolytics are designed for superior selectivity and in vivo stability, enabling targeted elimination of these pro-aging cells while sparing healthy tissue. SR-002 targets pulmonary senescence in IND-enabling studies.
NAD+ Metabolic Pathway
NAD+ is a critical cofactor in cellular energy metabolism and DNA repair, and its decline with age underpins many of the hallmarks of cellular aging. Our small molecule and biologic approaches target the biosynthetic and salvage pathways that govern NAD+ homeostasis, with the goal of restoring metabolic resilience in aging tissues. SR-003 is in active discovery for metabolic aging indications.
Programs in development.
| Program | Mechanism | Stage | Target Indication |
|---|---|---|---|
| SR-001 | Epigenetic Reset |
Preclinical
|
Aging-Associated Fibrosis |
| SR-002 | Senolytic |
IND-Enabling
|
Pulmonary Senescence |
| SR-003 | NAD+ Modulator |
Discovery
|
Metabolic Aging |
Our Founder
Founder & Chief Executive Officer
Our founder received her PhD in Molecular Biology from MIT and completed postdoctoral research at the Salk Institute. She has published over 40 papers on epigenetic clocks and senescence biology, with her work cited in leading journals including Nature, Cell, and Science. Prior to founding Shift, she led aging programs at a leading biotechnology firm, overseeing the development of novel senolytic and reprogramming therapeutics from early discovery through IND-enabling studies.